AI Summary & Key Takeaways
AI InsightThe 5-year DFS for patients with a tumor diameter of 35 mm (P = 0.128).Conclusion: Tumor size was not a risk factor predicting recurrence in patients with stage I or II endometrioid-type endometrial cancerwho had lymphadenectomy.
📌 3 Key Takeaways
Abstract
Background/aim: We aimed to define the effect of tumor size on recurrence and survival rates in patients with stage I–II endometrioidtype endometrial cancer.Materials and methods: A total of 550 patients who had total abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvicparaaortic lymphadenectomy were included. Patients with extrauterine spread, sarcomatous components, or synchronized tumor andthose who did not undergo lymphadenectomy or did not have data on tumor size were excluded.Results: The median tumor size was 35 mm (range: 3–335 mm). According to the 2009 International Federation of Obstetrics andGynecology (FIGO) criteria, 245 cases were defined as stage IA, 271 as stage IB, and 34 as stage II. The 5-year disease-free survival (DFS)rate was 92% and the 5-year disease-specific survival (DSS) rate was 99%. The effects of prognostic factors on DFS were evaluated. Olderage, stage II disease, deep myometrial invasion, and receiving adjuvant radiotherapy were associated with decreased DFS. There was nostatistically significant association between tumor size and DFS. The 5-year DFS for patients with a tumor diameter of 35 mm (P = 0.128).Conclusion: Tumor size was not a risk factor predicting recurrence in patients with stage I or II endometrioid-type endometrial cancerwho had lymphadenectomy.